A Phase 1b/2 study of rebastinib (DCC-2036), a selective and potent inhibitor of Tie2, in combination with paclitaxel in patients with advanced or metastatic solid tumors, including IBC, is ongoing (ClinicalTrials.gov Identifier: NCT03601897; An Open-Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid Tumors; Table 1) [115]. This evidence concerns the gene TEK and inflammatory breast carcinoma.